# This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa

> **NCT02052661** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 301 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Engerix™-B Kinder

## Key facts

- **NCT ID:** NCT02052661
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-18
- **Primary completion:** 2014-09-23
- **Final completion:** 2014-09-23
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052661, "This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02052661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*